Serious illness is a leading factor in personal-bankruptcy cases in the United States. There’s a complex web around who is paying for care: Hospitals? Insurance companies? Patients themselves?
What’s to be done about high drug prices, and can we find a bipartisan solution?
Scott Gottlieb, Commissioner of the US Food and Drug Administration discusses drug pricing.
What are the novel models delivering breakthroughs? How can precision and partnership drive value?
The future of prescription drugs.
Macroeconomic pressures have hit the R&D returns of life sciences firms.